- 3.4Impact Factor
- 9.9CiteScore
- 20 daysTime to First Decision
Vaccines, Volume 9, Issue 5
May 2021 - 126 articles
Cover Story: Considering that SARS-CoV-2 is mainly mucosally transmitted, a therapy administered via this same route may represent a desirable approach to fight SARS-CoV-2 infection. Experience over the past few decades has clearly demonstrated that a shift from traditional needle-based to needle-free immunization can overcome a number of limitations. Therefore, in this review, we highlight the potential of using genetically modified probiotics to express SARS-CoV-2 proteins with the aim of developing candidate oral vaccines that are capable of stimulating immune responses in the gut and lung to fight COVID-19. Indeed, the crosstalk and reciprocal interaction of the gut and lung mucosa (gut–lung axis) is mediated by immune cells moving between the two districts via the bloodstream and the lymphatic ducts, leading to modulation of the immune response at both sites. View this paper.
- Issues are regarded as officially published after their release is announced to the table of contents alert mailing list .
- You may sign up for email alerts to receive table of contents of newly released issues.
- PDF is the official format for papers published in both, html and pdf forms. To view the papers in pdf format, click on the "PDF Full-text" link, and use the free Adobe Reader to open them.
Articles
There are no articles in this issue yet.
Get Alerted
Add your email address to receive forthcoming issues of this journal.
Vaccines - ISSN 2076-393X